RIPK3 exhibits a U-shaped dose-response in AKI-to-CKD progression: Optimal therapeutic window and the TGF-β1-HMGB1 feedback loop

Key Points

• RIPK3 exhibits a U-shaped dose-response, indicating both low and high levels may worsen AKI-to-CKD progression.
• The study highlights a significant therapeutic window for RIPK3 intervention, which could optimize patient outcomes in kidney disease.
• Assessment reveals the TGF-β1-HMGB1 feedback loop plays a critical role in mediating these effects on kidney health.
• These findings underscore the need for careful consideration of RIPK3 levels to manage chronic kidney disease risks effectively.